MedTrace Logo

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

NCT00702494 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-03-16

No results posted yet for this study

Summary

TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented.

In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Conditions

Interventions

BIOLOGICAL

TB-403

Multiple IV

Sponsors & Collaborators

  • Oxurion

    collaborator INDUSTRY

  • BioInvent International AB

    lead INDUSTRY

Principal Investigators

  • Ulrik Lassen, MD, PhD · Rigshospitalet, Denmark

  • Lena Winstedt, PhD · BioInvent International AB

  • Dorthe Nielsen, MD, PhD · Herlev Hospital, Herlev, Denmark

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00702494 on ClinicalTrials.gov